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Abstract
Background: Preeclampsia is a common obstetrical disease affecting 3-5% of pregnancies and representing one of
the leading causes of both maternal and fetal mortality. Maternal symptoms occur as an excessive systemic
inflammatory reaction in response to the placental factors released by the oxidatively stressed and functional
impaired placenta. The T-cell immunoglobulin domain and mucin domain (TIM) family is a relatively newly described
group of molecules with a conserved structure and important immunological functions. Identification of Galectin-9 as
a ligand for TIM-3 has established the Galectin-9/TIM-3 pathway as an important regulator of Th1 immunity and
tolerance induction.
Methods: The aim of our study was to investigate the expression and function of Galectin-9 and TIM-3 molecules by
peripheral blood mononuclear cells and the possible role of Galectin-9/TIM-3 pathway in the immunoregulation of
healthy pregnancy and early-onset preeclampsia. We determined TIM-3 and Gal-9 expression and cytotoxicicty of
peripheral lymphocytes of early-onset preeclamptic women and healthy pregnant woman using flow cytometry.
Results: Investigating peripheral lymphocytes of women with early-onset preeclampsia, our results showed a
decreased TIM-3 expression by T cells, cytotoxic T cells, NK cells and CD56dim NK cells compared to healthy
pregnant women. Interestingly, we found a notably increased frequency of Galectin-9 positive cells in each
investigated lymphocyte population in the case of early-onset preeclamptic patients. We further demonstrated
increased cytotoxic activity by cytotoxic T and CD56dim NK cells in women with early-onset preeclampsia. Our
findings showed that the strongest cellular cytotoxic response of lymphocytes occurred in the TIM-3 positive
subpopulations of different lymphocytes subsets in early-onset preeclampsia.
Conclusion: These data suggest that Gal-9/TIM-3 pathway could play an important role in the immune regulation
during pregnancy and the altered Galectin-9 and TIM-3 expression could result an enhanced systemic inflammatory
response including the activation of Th1 lymphocytes in preeclampsia.
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Introduction
Preeclampsia is a common obstetrical disorder of placental
origin with both local and systemic anomalies which is unique
to human. It affects about 3-5% of pregnancies representing
the leading cause of maternal, fetal and neonatal mortality and
morbidity worldwide [1,2]. It is usually manifested in the second
half of pregnancy with a classical triad of maternal symptoms:
hypertension, proteinuria and edema [3]. Although the
diagnosis is based on these late clinical findings, preeclampsia
is thought to be an implantation disorder.
The actual hypothesis regarding the etiology of preeclampsia
centers inadequate trophoblast invasion and placentation
presumably as a result of maladaptation of maternal immune
responses locally [4,5]. The immunological recognition of the
fetus and its subsequent immunotolerance by the maternal
immune system is not only the question of rejection or
acceptance but it also plays a central role in implantation and
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placentation. Polymorphic paternal antigens expressed by
extravillous cytotrophoblast provoke an inflammatory response
in the decidua leading to the loosening of the tissue and
facilitating trophoblast invasion and spiral artery remodeling.
The recognition of monomorphic paternal antigens will limit the
depth of placentation by activating local immunotolerance
mechanisms of the mother [6,7]. In the case of preeclampsia,
the invading trophoblast becomes excessively inhibited from
the beginning on resulting in poor placentation and in a small
sized placental mass [8–10].
The small placenta decompensate continuously when fetal
growth is accelerated (usually from week 20 on) and maternal
symptoms occur resulting from intrinsic factors
(syncytiotrophoblast microvesicles-STBM, anti-angiogenetic
factors, sFlt-1) released by the hypoxic and oxidatively
stressed placenta into the systemic circulation [11–14].
In the background of the clinical manifestation of the disease
there is a generalized systemic inflammatory response and an
endothelial dysfunction [15]. Circulating STBM act pro-
inflammatory and induce the secretion of TNF-α [16,17], IL-6
[16,18], IFN-γ [19] leading to the development of Th1 type
immunity [20].
In earlier works, our group demonstrated the involvement of
the innate immunity in the pathogenesis of the inflammatory
stage of the disease, showing that in preeclampsia, peripheral
γδ T cells and invariant NKT cells display an increased
cytotoxic potential, which may be due to altered expression of
NK cell inhibitory and activating receptors [21,22].
According to the current concept, preeclampsia is subdivided
in early (before 34 weeks) and late onset (after 34 weeks)
preeclampsia [4]. The major difference between the two clinical
forms is the etiological role of poor placentation. The early
onset type is considered to represent the “real preeclampsia”
with the pathomechanism described above. Late onset
preeclamptic patients have diseases/conditions like diabetes
mellitus, anemia, altitude sickness or multiple pregnancies,
where the placenta compensatory enlarges due to maternal
hypoxia and microvascular diseases [4].
The T-cell immunoglobulin and mucin domain (TIM) family is
a relatively newly described group of molecules with a
conserved structure and important immunological functions
[23,24]. A growing body of evidence supports the critical role of
different TIM molecules as modulators of the immune response
in transplant tolerance [25–27]. TIM-3 is a type I
transmembrane protein that contains no defined signaling
motifs in its cytoplasmic domain, but it has been implicated
both in activation and inhibition of immune responses [28,29].
TIM-3 is expressed in a variety of immune cells, including
CD8+ T cells [30], NK cells [31], NKT cells, Th17 cells,
regulatory T cells, dendritic cells, monocytes, macrophages
and mast cells. Therefore, there is mounting evidence that
TIM-3 is a potent regulator of both the adaptive and innate
immune response.
Identification of Galectin-9 (Gal-9) as a ligand for TIM-3 has
established the Gal-9/TIM-3 pathway as an important regulator
of Th1 immunity and tolerance induction [27,32,33].
Engagement of TIM-3 by its ligand Gal-9 negatively regulates
IFN-γ secretion, influences the ability to induce T cell tolerance
and triggers a significant signal cascade to induce apoptosis of
Th1 type immune cells. Ndhlovu et al. and others observed that
increased amounts of TIM-3 on T cells during HIV, hepatitis C
virus, and other chronic viral infections correlated with T-cell
dysfunction, suggesting that TIM-3 is also part of a regulatory
pathway during T cell exhaustion [34–36].
Although data about the role of Gal-9/TIM-3 pathway in the
pathogenesis of human diseases is emerging, data about their
role during human pregnancy and feto-maternal immunological
relationship is scarce. Taken the fact that in the second, clinical
stage of preeclampsia a maternal systemic inflammatory
response develops we can assume that the immunoregulatory
systems fail to control inflammation and maintain the healthy
immunological balance. As a part of it, the Gal-9/TIM-3
pathway may also be affected. Therefore, the aim of our
present study was to investigate the expression of Gal-9 and
TIM-3 molecules by peripheral blood mononuclear cells in
healthy pregnancy and preeclampsia.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all participants.
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval by
the Regional Ethical Committee at the Faculty of Medicine,
University of Pécs.
Patients
27 women with the classical symptoms of early-onset
preeclampsia (hypertension, proteinuria and edema) were
included in the study. Hypertension was defined as a diastolic
blood pressure of ≥90 mmHg on two separate occasions within
a 24-h period, and proteinuria was defined by ≥0,3 g protein in
24-h urine collection. 25 healthy pregnant women appropriately
matched for gestational age formed the control group (Table 1).
Table 1. Patients’ demographic and gynecological
characteristics.
 
Healthy pregnant
women
Early-onset
preeclamptic womenP-value
No. of patients 25 27  
Age (years) (mean) 32,6±1,03 29,1±1,53 NS
Gestational age at sampling
(mean) 35,64±0,27 33,74±0,48 NS
Gestational age at birth
(mean) 38,9±0,27 34,1±0,64 P<0,05
Birth weight (mean) 3420±126,84 1881±148,28 P<0,05
Previous live birth/ patients 058±0,15 088±0,31 NS
Statistical comparisons were made by using the Student’s t-tests. The results were
expressed as the mean value±standard error of the mean (SEM). Differences were
considered significant when the value of P was equal to or less than 0.05. NS = not
statistically significant.
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Lymphocyte separation, cryopreservation and thawing
Peripheral blood mononuclear cells (PBMC) were separated
from heparinized venous blood on Ficoll-Paque gradient. After
washing the cells in RPMI 1640 medium the cells were counted
and centrifuged.
Resuspension was performed in human serum containing
10% DMSO for cryoprotection. Cells were aliquoted in cryovials
and stored in a -80oC mechanical freezer. Thawing was carried
out on the day of fluorescent cell labeling. Cryovials were
warmed up as quickly as possible in 37oC water bath and
DMSO was washed out twice in RPMI 1640 medium.
Antibodies
Freshly thawed PBMC were used for surface and
intracellular staining and analysis. The following monoclonal
antibodies were used: fluorescein isothiocyanate (FITC)-
conjugated anti-human CD3 (BD Pharmingen), FITC-
conjugated anti-human CD4 (BD Pharmingen), FITC-
conjugated anti-human CD107a (BD Pharmingen),
phycoerythrin (PE)-conjugated anti-human Galectin-9
(Biolegend), PE-conjugated anti-human TIM-3 (R&D Systems),
allophycocyanin (APC)-conjugated anti-human CD56 (BD
Pharmingen), APC-conjugated anti-human CD8 (BD
Pharmingen), APC-conjugated anti-human FoxP3
(eBioscience). Control antibodies included isotype-matched
FITC-conjugated, PE-conjugated and APC-conjugated mouse
antibodies (all from BD-Pharmingen).
Peripheral blood lymphocyte populations detected by
flow cytometry
T cells (CD3+ cells), helper T cells (CD3+/CD4+), cytotoxic T
cells CD3+/CD8+ cells), regulatory T cells (CD4+/FoxP3+
cells), NK cells (CD3-/CD56+ cells), CD56dim NK cells (CD3-/
CD56dim+ cells), CD56bright NK cells (CD3-/CD56bright+ cells), and
NKT cells (CD3+/CD56+ cells).
Labeling of lymphocytes and flow cytometric analysis
106 thawed PBMC in 100 μl PBS/tube was incubated for 30
minutes at room temperature with the fluorochrome-labeled
monoclonal antibodies. Finally, the cells were resuspended in
300 μl PBS containing 1% paraformaldehyde, and stored at
4oC in dark until FACS analysis.
Labeled cells were analyzed with a FACSCalibur flow
cytometer (BD Immunocytometry Systems, Erembodegen,
Belgium) equipped with the CellQuest software program (BD
Biosciences, San Diego, CA, USA) for data acquisition and
analysis.
CD107a functional assay
To determine CD107a surface expression by cytotoxic T
cells and NK cells, PBMC were incubated for 4 h at 37° C in
the presence of FITC-conjugated anti-human CD107a
monoclonal antibody in RPMI 1640 medium containing 10%
fetal bovine serum, penicillin and streptomycin, ionomycin
(Sigma–Aldrich) and phorbol myristate acetate (Sigma–
Aldrich). After stimulation the cells were washed and
resuspended in PBS then stained with antibodies to cytotoxic T
cell and NK cell markers (APC-conjugated anti-human CD8 or
APC-conjugated anti-human CD56) together with PE-
conjugated anti-human TIM-3 antibody for 30 min at room
temperature at dark. The cells were washed in PBS, fixed with
1% paraformaldehyde and evaluated by FACS.
FoxP3 staining
After surface labeling intracellular staining of Foxp3 was
performed using the FoxP3 Staining Buffer Set (eBioscience)
according to the manufacture’s protocol. Briefly, cells were
permeabilized in 1 ml fixation/permeabilization buffer
(Concentrate/Diluent 1:4) at 4° C for 1 h. Washed twice in
buffer and stained afterwards with the anti-human FoxP3
monoclonal antibody at 4° C for 1 hour. Flow cytometric
analysis was performed on a FACSCalibur flow cytometer
(Becton Dickinson).
Statistical analysis
Statistical comparisons were made by using the Student’s t-
tests. The results were expressed as the mean ± SEM.
Differences were considered significant for P ≤ 0.05.
Results
1: Phenotype analysis of peripheral blood mononuclear
cells in women with early-onset preeclampsia and in
healthy pregnant women
As shown in Table 2 we compared the frequency of T cells,
helper and cytotoxic T cell subpopulations, regulatory T cells,
NK cells, CD56dim NK cells, CD56bright NK cells, and NKT cells
among peripheral blood mononuclear cells in women with
early-onset preeclampsia and in healthy pregnant women.
Compared to healthy pregnant controls, in the peripheral
blood of early-onset preeclamptic women there is a significant
decrease in the frequency of regulatory T cells (0,92±012 vs.
0,55±0,08) and in the frequency of CD56bright cells (1,41±0,12
vs. 0,61±0,13).
Table 2. Peripheral blood mononuclear cell phenotype
characteristics in women with early-onset preeclampsia and
in healthy pregnant women.
 
Healthy pregnant
women
Early-onset preeclamptic
women P-value
CD3+ T cells 67,51±1,5 66,1±4,39 NS
CD4+ T cells 39,98±2,93 37,53±2,98 NS
CD8+ T cells 31,29±2,52 29,92±2,52 NS
Regulatory T cells 0,92±0,12 0,55±0,08 P<0,05
CD3-CD56+ cells 9,91±0,94 8,12±1,25 NS
CD3-CD56dimcells 8,53±0,92 7,54±1,15 NS
CD3-CD56bright cells 1,41±0,12 0,61±0,13 P<0,01
CD3+CD56+ cells 5,11±1,18 3,35±1,11 NS
In both groups, statistical comparisons were made by using the Student’s t-tests.
The results were expressed as the mean value±standard error of the mean (SEM).
Differences were considered significant when the value of P was equal to or less
than 0.05. NS = not statistically significant.
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2: Differential expression of TIM-3 on peripheral blood
mononuclear cell subsets in healthy pregnant women
We measured the surface expression of TIM-3 on helper,
cytotoxic T cells, NK cells, NK cell subsets and NKT cells by
flow cytometry. We observed high surface expression of TIM-3
on most NK cells (median 77,9%) compared with T cells
(median 3,7%), cytotoxic (median 13,8%), helper (median
2,2%) T cells or NKT cells (median 5%). CD56dim NK cells are
considered mature NK cells and are differentiated from
immature CD56bright NK cell subset. We observed that the
majority of CD56dim NK cells expressed TIM-3 (median 79,8%),
whereas CD56bright NK cells showed a lower level of TIM-3
expression (median 67,6%).
3: TIM-3 expression by peripheral blood mononuclear
cells in women with early-onset preeclampsia and in
healthy pregnant women
Investigating peripheral blood mononuclear cells of women
with early-onset preeclampsia, our results showed a decreased
TIM-3 expression by T cells, cytotoxic T cells (Figure 1A), NK
cells (Figure 1B) and CD56dim NK cells (Figure 1C) compared
to healthy pregnant women (T cells: 2,04±0,3 vs. 3,7±0,22;
cytotoxic T cells: 7,10±1,78 vs. 13,83±1,17; NK cells:
61,12±2,42 vs. 77,95±2,23; CD56dim NK cells: 60,75±2,4 vs.
79,86±,19).
4: Gal-9 expression by peripheral blood mononuclear
cells in women with early-onset preeclampsia and in
healthy pregnant women
Analyzing the Gal-9 expression of peripheral lymphocytes we
found a notably increased frequency of Gal-9 positive cells in
each investigated lymphocyte population and subpopulation (T
cells, cytotoxic T cells, NK cells, CD56dim NK cells, CD56bright
NK cells and NKT cells) in the case of early-onset preeclamptic
patients when compared to healthy pregnant controls (Figure
2A,B). The results are statistical significant in all investigated
group except helper T cells, NKT cells and Treg cells (Figure
2C) (T cells: 23,09±3,42 vs. 8,45±1,07; cytotoxic T cells:
20,17±2,87 vs. 8,47±1,17; NK cells: 25,29±2,28 vs.
14,94±1,88; CD56dim NK cells: 25,95±2,49 vs. 16,3±2,1;
CD56bright NK cells: 19,36±2,63 vs. 8,26±1,12).
5: Cytotoxicity of peripheral cytotoxic T cells and NK
cells in women with early-onset preeclampsia and in
healthy pregnant women
Investigating the cytotoxic activity of cytotoxic T and NK
cells, we found that only TIM-3 positive cytotoxic T (Figure
3A,B) and NK cells (Figure 3C,D) showed increased
cytotoxicity in women with early-onset preeclampsia compared
to healthy pregnant women (cytotoxic T cells: 13,11±1,48 vs.
6,15±1,09; NK cells: 30,02±5,04 vs. 14,32±2,57).
Interestingly, TIM-3 positive CD56dim NK cells from women
with early-onset preeclampsia showed significantly increased
CD107a expression compared to healthy pregnant women and
this difference was not observed in the case of CD56bright NK
cells (CD56dim NK cells: 28,53±4,88 vs. 12,68±2,32). Overall,
TIM-3 marked the most responsive subset NK cells with
respect to degranulation, as marked by CD107a expression.
Analyzing the cytotoxicity of the investigated lymphocyte
populations and subpopulations regardless of TIM-3
expression no differences were found between early-onset
preeclamptic patients and healthy pregnant donors (data not
shown).
Discussion
The maternal immune system plays a central role in the
pathogenesis of preeclampsia, although in different ways, at
different sites and with different components in the pre-clinical
and clinical stages of the disease. First, there is an immune
maladaptation locally to cellular processes of implantation and
subsequent trophoblast invasion resulting in a placenta with
restricted oxygen and nutrient transfer capacity. In this case
cellular lymphoid elements recruited in the decidua are
responsible for inadequate operating. These cells are pre-
dominantly part of the innate immune system: NK cells, NKT
cells, γδ T cells. Maternal symptoms occur when the small
sized placenta decompensate, i.e. the result of the placentation
disorder becomes the causative agent of the clinical syndrome.
At this stage, a systemic non-specific inflammatory response
develops induced by placental factors released in the maternal
circulation with the involvement of both innate and adaptive
immunity. Recognition of placental particles by monocytes and
dendritic cells triggers the release of pro-inflammatory
cytokines, the key elements for the generalization and
exaggeration of inflammatory reactions.
As long as the placenta exists in the uterus the symptoms
will persist, even after birth. This fact suggests the failure of
immune regulatory mechanism which could dampen long-term
inflammatory processes. Several studies confirmed a
decreased number and function of regulatory T cells in
preeclamptic patients [37]. Treg cells act immunosuppressive
by various strategies including inhibitory cytokine secretion
(TGF-β, IL-10), direct cytolysis, metabolic disruption and
inhibition of dendritic cells [38].
The functional role of Gal-9/TIM-3 pathway was first
described as a mechanism to negatively regulate Th1
responses, inhibiting IFN-γ production and inducing cell death.
Subsequently, this interaction has been described to have
important roles in transplantation immunity, infection,
autoimmunity, inflammation and tumor immunity.
Although data about the role of Gal-9/TIM-3 pathway in the
pathogenesis of human diseases is emerging, data about their
role during human pregnancy is scarce. Our earlier study
showed that activated γδ T cells of preeclamptic women have
increased cytotoxic potential, which may be due to altered
expression of TIM-3 receptor [22]. A recent study by Chabtini et
al. showed the possible role of TIM-3-expressing innate
immune cells in the regulation of tolerance at the fetomaternal
interface using an allogeneic mouse model of pregnancy [39].
The only other human study done by Zhao et al. reported that
TIM-3 is up-regulated by monocytes in peripheral blood of
pregnant women indicate that abnormal TIM-3 expression level
might be connected to the pregnancy loss [40].
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These data suggest that Gal-9/TIM-3 pathway could play an
important role in the immunoregulation during pregnancy and
the altered Galectin-9 and TIM-3 expression could result in an
enhanced systemic inflammatory response including the
activation of Th1 lymphocytes and type-1 bias in preeclampsia.
In this study we have examined the expression and function
of a novel immune receptor TIM-3 in peripheral blood of
women with early-onset preeclampsia as our aim is to study
the role of TIM-3 positive lymphocyte subpopulations in the
maternal syndrome of early-onset preeclampsia with a
maternal systemic inflammatory disorder of the second half of
pregnancy. During healthy pregnancy NK cells have the
highest percentage of cells expressing TIM-3. We observed
that the majority of CD56dim NK cells expressed TIM-3, whereas
CD56bright NK cells, helper, cytotoxic T cells and NKT cells
showed a much lover level of TIM-3 expression. Investigating
peripheral blood mononuclear cells of women with early-onset
preeclampsia, our results showed a decreased TIM-3
expression by T cells, cytotoxic T cells, NK cells and CD56dim
NK cells compared to healthy pregnant women. Interestingly,
we found a notably increased frequency of Galectin-9 positive
cells in each investigated lymphocyte population and
subpopulation (T cells, cytotoxic T cells, NK cells, CD56dim NK
cells, CD56bright NK cells and NKT cells) in the case of early-
Figure 1.  TIM-3 expression by peripheral lymphocytes in women with early-onset preeclampsia and in healthy pregnant
women.  The expression of TIM-3 by cytotoxic T cells, NK cells, CD56dim NK cells and CD56bright NK cells in the peripheral blood of
women with early-onset preeclampsia and in healthy pregnant women. The solid bars represent medians of 10 and 11
determinations, respectively, the boxes indicate the interquartile ranges and the lines show the most extreme observations.
Differences were considered statistically significant for P-values ≤0.05.
NS = not statistically significant.
doi: 10.1371/journal.pone.0071811.g001
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onset preeclamptic patients when compared to healthy
pregnant controls.
We further demonstrated increased cytotoxic activity by
cytotoxic T and CD56dim NK cells in women with early-onset
preeclampsia. One possible mechanistic explanation is that
lower expression of surface TIM-3 on immune cells during
early-onset preeclampsia may allow cytotoxic T and NK cells to
escape Gal-9-induced negative regulation, ultimately leading to
uninhibited expansion of Th1 and Th17 response and to
persistent inflammatory response usually seen during early-
onset preeclampsia. Contrary to these findings however, the
percentage of Gal-9 positive effector immune cells (cytotoxic T
and NK cells) - except helper and regulatory T cells - were
significantly higher in the peripheral blood of patients with
preeclampsia than in healthy individuals suggesting a
dysfunctional Gal-9 mediated regulatory response.
CD56bright NK cells have been labeled ‘immunoregulatory’
based on their ability to secrete cytokines [41] and home to
lymph nodes and tissues and their expansion in humans during
states characterized by increased immune tolerance such as
healthy pregnancy [42]. Since expanded CD56bright NK cells can
limit the survival of activated T cells in vitro in a contact-
dependent manner [43] we hypothesize that the increased
Gal-9 expression by CD56bright NK cells could be a
Figure 2.  Gal-9 expression by peripheral lymphocytes in women with early-onset preeclampsia and in healthy pregnant
women.  The expression of Galectin-9 by cytotoxic T cells, NK cells, and regulatory T cells in the peripheral blood of women with
early-onset preeclampsia and in healthy pregnant women. The solid bars represent medians of 9 and 11 determinations,
respectively, the boxes indicate the interquartile ranges and the lines show the most extreme observations. Differences were
considered statistically significant for P-values ≤0.05.
NS = not statistically significant.
doi: 10.1371/journal.pone.0071811.g002
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compensatory mechanism as they frequency is significantly
decreased during early-onset preeclampsia.
Bielekova et al. published that daclizumab therapy resulted
in a gradual expansion of CD56bright NK cells that correlated
with the decrease in brain inflammation in multiple sclerosis
patients [43,44]. This suggests that daclizumab therapy could
facilitate the ability to ultimately modulate Gal-9/TIM-3 pathway
for therapeutic benefit.
Further investigations are needed to clear whether the Gal-9-
TIM-3 interactions display different immunological responses in
healthy pregnant and early-onset preeclamptic women, partially
due to the altered expression of these molecules on the cell
surface of peripheral lymphocytes.
Anyway, our findings that the strongest cellular cytotoxic
response of lymphocytes occurred in the TIM-3 positive
subpopulation of different lymphocytes subsets underlines the
fact, that the involvement of the immunoregulatory receptor
TIM-3 in the pathogenesis of the systemic inflammatory
response observed in early-onset preeclampsia is
incontestable and represents theoretically a site of therapeutic
intervention for immune suppression.
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